-
Merck KGaA Collaborates with Biotheus to Accelerate Cell Line Characterization
•
German pharmaceutical giant Merck KGaA (ETR: MRK) has announced a collaboration with Biotheus, a China-based biotech company focused on developing treatments for cancer and autoimmune diseases. The partnership aims to streamline Biotheus’ development process by utilizing Merck’s Blazar Rodent Panel, which significantly reduces the turn-around-time (TAT) of cell line characterization…
-
Merck’s Keytruda Receives 10th Indication Approval in China for TNBC
•
US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has obtained its 10th indication approval from China’s National Medical Products Administration (NMPA). The drug can now be used to treat early high-risk triple negative breast cancer (TNBC) with tumors expressing PD-L1 (CPS ≥ 20) in…
-
Takeda Partners with CCCMHPIE to Boost Rare Disease Drug Access in China
•
The 5th China International Import Expo (CIIE) saw Japan-based Takeda Pharmaceutical Co., Ltd’s China unit announce a partnership with the China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE). The collaboration aims to enhance professional collaborations in the rare disease field. Financial details of the…
-
Xellsmart Raises RMB 200M in Series A1 Round for Stem-Cell Therapies
•
Xellsmart, a stem-cell startup based in Suzhou, has reportedly raised over RMB 200 million (USD 27.6 million) in a Series A1 financing round. The round was co-led by Qiming Venture Partners, Lilly Asia Ventures, Xiamen Jinyuan Zhanhong Investment, and China-Singapore Suzhou Industrial Park Development Group. Other investors included Oriza Holdings,…
-
Novo Nordisk Reports 16% YOY Growth in Q3, Raises Full-Year Guidance
•
Denmark-based biopharma Novo Nordisk A/S (NYSE: NVO) has released its Q3 2022 earnings report. The company reported a 16% year-on-year (YOY) growth in constant exchange rates (CER) to DKK 128.9 billion (USD 17.3 billion) over the 9-month period. Sales for the three-month Q3 period were up 15% (CER) to DKK…
-
Novo Nordisk Partners with Shanghai Pharma for Smart Logistics at CIIE
•
Novo Nordisk (NYSE: NVO) has announced a strategic partnership with China’s Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) unveiled at the 5th China International Import Expo (CIIE). The Denmark-based major will be provided with smart and modern logistics warehouses, enabling intensive, standardized, information-based, and intelligent drug logistics management and operation for…
-
SIMR Biotechnology Raises RMB 150M in Series C1 Financing Round
•
China’s Shanghai SIMR Biotechnology Co., Ltd has reportedly raised RMB 150 million (USD 20.7 million) in a Series C1 financing round, alongside “tens of millions” in bank loans. Investors included Guanzi Private Fund Management, Tian Rui Feng Nian, and Yixing Huarui. The proceeds will be used to support pre-clinical development,…
-
PingAn Good Doctor Partners with Roche and OrigiMed at CIIE
•
The 5th China International Import Expo (CIIE) saw China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good Doctor, announce partnerships with Swiss giant Roche and its compatriot firm OrigiMed, a precision medicine company. The collaboration aims to expand the pan-solid tumor payment service mode,…
-
Organon Partners with Alibaba Health to Enhance Chronic Disease Management
•
Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, has announced another strategic deal at the 5th China International Import Expo (CIIE). This time, Organon is partnering with Alibaba Health Information Technology Ltd…
-
Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study
•
China-based Qilu Pharmaceutical has published the latest results from a Phase II clinical study for QL1706, a dual-targeted antibody against programmed death 1 (PD-1) and cytotoxic T lymphocyte-associated antigen-4 (CTLA-4). The findings were presented at the Chinese Society of Clinical Oncology (CSCO) annual meeting. Study Design and ResultsPrevious clinical studies…
-
Organon Sponsors Retail Pharmacy Health Center at CIIE
•
The 5th China International Import Expo (CIIE) saw Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, sponsor the Retail Pharmacy Health Center of Excellence. This program is hosted by the China Association…
-
Sanofi Partners with China Resources Sanjiu at CIIE for Consumer Healthcare
•
The 5th China International Import Expo (CIIE) saw Sanofi’s consumer healthcare unit announce a partnership with China Resources Sanjiu Medical & Pharmaceutical Co., Ltd (SHE: 000999). This collaboration marks a significant milestone in the companies’ ongoing efforts to enhance consumer healthcare in China. Partnership History and RenewalThe two companies first…
-
Sumitomo Dainippon Partners with Profex to Promote Antipsychotics in China
•
Japan-based Sumitomo Dainippon Pharma Co., Ltd has announced a partnership with Profex, a trade company in Shanghai. The collaboration aims to promote Lonasen (blonanserin) and Latuda (lurasidone), both antipsychotic medications, in the Chinese market. Financial details of the partnership were not disclosed. Epidemiological ContextAccording to the latest epidemiological survey in…
-
Eli Lilly Partners with AmoyDx and Burning Rock for Retevmo Companion Diagnostics
•
The 5th China International Import Expo (CIIE) saw US-based Eli Lilly (NYSE: LLY) announce a partnership with China-based Amoy Diagnostics Co., Ltd (AmoyDx) and Burning Rock Biotech Ltd (NASDAQ: BNR). The collaboration aims to enhance the development of companion diagnostics (CDx) for Retevmo (selpercatinib), the world’s first highly-selective RET kinase…
-
BioNTech’s Comirnaty Gets Limited Authorization in China Amid Scholz Visit
•
Germany-based mRNA specialist BioNTech (NASDAQ: BNTX) reportedly benefited from German Chancellor Olaf Scholz’s visit to China this week. Chinese authorities agreed to a limited authorization for the mRNA-based COVID-19 vaccine Comirnaty (BNT162b2) to be used by German national expatriates living in China, according to media sources including Bloomberg, quoting Scholz.…
-
Organon’s Q3 Results Show Women’s Health Segment Outperforms Amid Global Revenue Decline
•
US-based Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, released its Q3 2022 financial results. Total global revenues were down 4% year-on-year (YOY) in real terms to USD 1.537 billion, but up…
-
Organon Signs MOU with China’s National Health Commission at CIIE
•
Organon & Co. (NYSE: OGN), a firm with a strong focus on women’s health that split from Merck, Sharp & Dohme (MSD, NYSE: MRK) in mid-2021, announced at the 5th China International Import Expo (CIIE) the signing of a memorandum of understanding (MOU) with the National Health Commission (NHC). The…
-
Ascletis Pharma Presents Phase I Study Results for ASC43F at AASLD
•
China-based Ascletis Pharma Inc. (HKG: 1672) made a poster presentation detailing the abstract of a Phase I study for ASC43F in a single dose to treat non-alcoholic steatohepatitis (NASH) at The Liver Meeting 2022 of the American Association for the Study of Liver Diseases (AASLD). The presentation highlighted the drug’s…
-
Ji Xing Pharmaceuticals’ Omecamtiv Mecarbil Accepted for Review by CDE
•
Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that a market filing for its investigational omecamtiv mecarbil has been accepted for review by the Center for Drug Evaluation (CDE). The small molecule is a potential first-in-class cardiac myosin activator being developed as a treatment for heart failure with reduced…
-
Sophway Raises ‘Tens of Millions’ in Angel Round for Endoscope Development
•
Sophway Technology, a full HD endoscope system developer based in Shenzhen, has reportedly raised “tens of millions” of renminbi in an angel financing round. The round was led by Bioching Capital, with contributions from Vinno Capital and TusStar. The proceeds will be used to advance the domestic development of endoscope…
